Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:16 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Lemborexant for the Treatment of Residual Insomnia in Major Depressive Disorder (MDD)
NCT06843187 · Unity Health Toronto · PHASE2 · terminated · last registry update 2026-07-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funding withdrawn by sponsor.” | – | Registry record, Unity Health Toronto |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HCRTR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-04Also stopped (terminated): Institute for Advanced Medical Research, Alpharetta, GA, suvorexant + Placebo (NCT02669030)
- 2026-10-20Results posted on the registry: Johns Hopkins University, Suvorexant + Placebos (NCT04287062)
- 2026-09-28Phase 3 first posted: Idorsia Pharmaceuticals Ltd., Daridorexant + Placebo (NCT07843329)
- 2026-08-12Results posted on the registry: Medical University of South Carolina, Suvorexant Tablets (NCT06162663)
- 2026-08-12Also stopped (terminated): Medical University of South Carolina, Suvorexant Tablets (NCT06162663)
- 2026-07-23Results posted on the registry: Columbia University, Suvorexant + Placebo (NCT05823844)
- 2026-06-30Also stopped (suspended): Global Coalition for Adaptive Research, Intervention C Daridorexant + Intervention C Placebo (NCT05948540)
- 2026-06-30Also stopped (suspended): Global Coalition for Adaptive Research, Intervention A Fluoxetine Hydrochloride (HCl) + Intervention A Placebo (NCT05422612)
- 2026-05-28Also stopped (terminated): Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal, Lemborexant 5 MG [Dayvigo] (NCT06231641)
- 2026-04-16Results posted on the registry: Brigham and Women's Hospital, Suvorexant + Placebo (NCT05593653)
- 2026-03-24Results posted on the registry: Baylor College of Medicine, Lemborexant 10 mg + Naltrexone (NCT05458609)
- 2026-02-04Results posted on the registry: University of California, San Francisco, Lemborexant + Placebo (NCT05344443)
- 2026-01-15Results posted on the registry: Duke University, Suvorexant 20 mg + Placebo (NCT05733286)
- 2025-12-23Results posted on the registry: Johns Hopkins University, Suvorexant (dual orexin receptor antagonist) + Placebo (NCT05546515)
- 2025-10-30Results posted on the registry: University of Maryland, Baltimore, suvorexant (or placebo) (NCT05908526)
- 2025-10-30Results posted on the registry: Ohio State University, Suvorexant (NCT05656534)
- 2025-10-27Results posted on the registry: Beth Israel Deaconess Medical Center, Suvorexant 20 mg + Placebo oral tablet (NCT04092894)
- 2025-10-01Results posted on the registry: The University of Texas Health Science Center, Houston, Suvorexant 20 mg + Suvorexant 0mg (NCT04234997)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision